+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of BDB-001 injection combined with cyclophosphamide followed by azathioprine, or combined with rituximab, in inducing remission in adults with active anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis AAV. This phase III, randomized, double-blind trial aims to compare BDB-001 treatment against prednisone in similar combinations. The study is sponsored by Staidson Beijing Biopharmaceuticals Co., Ltd and focuses on patients aged 18 to 75 years diagnosed with granulomatosis with polyangiitis or microscopic polyangiitis. Participants are assigned to one of two groups one receives BDB-001 injection plus cyclophosphamideazathioprine or rituximab with a prednisone-matching placebo, while the other receives a placebo injection plus cyclophosphamideazathioprine or rituximab with a full starting dose of prednisone. All drugs are administered intravenously. The study measures remission at 24 weeks, with extended follow-up to evaluate sustained remission, relapse timing, kidney function, glucocorticoid toxicity, and quality of life through 48 weeks. Throughout the trial, participants undergo regular assessments using the Birmingham Vasculitis Activity Score BVAS to monitor disease activity and remission status. Additional evaluations include kidney function tests, glucocorticoid dosages, damage indices, and health-related quality of life questionnaires. Safety and treatment impact are carefully monitored, with the study lasting until February 2028. The primary outcome is the proportion of patients achieving disease remission at week 24.

Age: 18Years - 75YearsAll GendersPhase 3
65 locations
P

Actively Recruiting

Researchers are studying the effects and safety of SR1375 in hospitalized adults with community-acquired pneumonia CAP. This phase 2, randomized, double-blind, placebo-controlled study aims to evaluate SR1375 compared to placebo in patients who have not improved after initial standard pneumonia treatment. The study includes adults aged 18 to 85 years and is sponsored by Shanghai SIMR Biotechnology Co., Ltd. Participants will be randomly assigned to one of four groups to receive either 0.3 mg, 1 mg, or 3 mg of SR1375 capsules or a placebo daily by mouth for 8 weeks, alongside their usual pneumonia treatments. The study includes a screening period, an 8-week double-blind treatment period, and a 14-day safety follow-up after treatment ends. During the study, participants will undergo assessments including the NIAID-OS 8-point scale to monitor pneumonia severity, oxygen levels, and other health measures up to 56 days. Researchers will track outcomes such as oxygenation, mortality, hospitalization duration, and readmission rates. The total participation time for each patient is up to 10 weeks, with close monitoring of safety and health status throughout the study.

Age: 18Years - 85YearsAll GendersPhase 2
29 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
E

Actively Recruiting

Researchers are conducting a Phase III clinical trial to evaluate the safety and effectiveness of OT202 ophthalmic solution for treating adults aged 30 to 75 years with moderate to severe dry eye. The study is randomized, double-blind, and placebo-controlled, aiming to compare OT202 with a placebo in improving dry eye symptoms. The main measures include changes in corneal staining and eye dryness scores after 56 days of treatment. Participants will be randomly assigned to receive either 1% OT202 eye drops or a placebo, both administered as 1 to 2 drops three times daily in the conjunctival sac. The study includes a screening period, a run-in phase, an 8-week double-blind treatment, and long-term safety follow-up cohorts lasting 10, 28, and 54 weeks. After the double-blind phase, all participants will receive open-label OT202. Pharmacokinetic assessments will be done in a subset of participants. During the study, participants will attend scheduled visits for eye exams, symptom assessments, and safety monitoring. Tests include corneal fluorescein staining, tear film break-up time, Schirmer I test, and various dry eye questionnaires. Researchers will monitor adherence to treatment and evaluate changes from baseline in key eye dryness measures. Follow-up continues for up to 54 weeks to observe long-term safety and effects, with total participation lasting several months depending on cohort assignment.

Age: 30Years - 75YearsAll GendersPhase 3
49 locations